Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last €57.69 EUR
Change Today +0.40 / 0.70%
Volume 229.6K
As of 11:37 AM 08/4/15 All times are local (Market data is delayed by at least 15 minutes).

galapagos nv (GLPG) Snapshot

Open
€57.33
Previous Close
€57.29
Day High
€58.38
Day Low
€56.50
52 Week High
08/4/15 - €58.38
52 Week Low
10/16/14 - €10.00
Market Cap
2.2B
Average Volume 10 Days
219.6K
EPS TTM
€-1.24
Shares Outstanding
38.9M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for GALAPAGOS NV (GLPG)

Related News

No related news articles were found.

galapagos nv (GLPG) Related Businessweek News

No Related Businessweek News Found

galapagos nv (GLPG) Details

Galapagos NV, a clinical stage biotech company, develops and commercializes novel medicines in Belgium, Croatia, France, and the Netherlands. Its products include GLPG0634, an orally-available selective inhibitor of Janus kinase 1, which is in Phase II clinical study for the treatment of rheumatoid arthritis and other inflammatory diseases; and GLPG1205/GLPG1690 that is in Phase IIA clinical study for treating inflammatory bowel disease, as well as in Phase II proof-of-concept study for the treatment of ulcerative colitis patients. The company is also developing MOR106, an antibody, which is in preclinical development stage for the treatment of inflammatory diseases; GSK2586184, an investigational compound that is in Phase II clinical study for the treatment of chronic immuno-inflammatory diseases consisting of SLE, psoriasis, and ulcerative colitis; and GLPG0974, an orally available small molecule, which is in Phase II clinical study to prevent free fatty acid-induced activation and migration of neutrophils towards an inflammatory site, such as in the gut of patients with inflammatory bowel disease. It has strategic alliances with GlaxoSmithKline, MorphoSys, Servier, and AbbVie to discover and develop small molecules for the treatment of inflammation, inflammatory diseases, osteoarthritis, oncology, rheumatoid arthritis/crohn’s disease, and cystic fibrosis diseases. The company was founded in 1999 and is headquartered in Mechelen, Belgium.

417 Employees
Last Reported Date: 05/14/15
Founded in 1999

galapagos nv (GLPG) Top Compensated Officers

Co-Founder, Chief Executive Officer, Managing...
Total Annual Compensation: €696.5K
Compensation as of Fiscal Year 2014.

galapagos nv (GLPG) Key Developments

Galapagos NV Completes Recruitment forORIGIN Phase 2 trial with GLPG1205 in ulcerative colitis patients

Galapagos NV announced it has completed recruitment for the Phase 2 Proof-of-Concept study in ulcerative colitis with GPR84 inhibitor GLPG1205. GPR84 was identified as a target for these diseases through Galapagos' target discovery platform and GLPG1205 is fully proprietary to Galapagos. GLPG1205 ('1205) inhibits GPR84, a novel mechanism of action for the treatment of inflammatory bowel diseases (IBD). GPR84 is upregulated in IBD patients. Galapagos has shown that 1205, a selective inhibitor of GPR84, is effective in pre-clinical models for IBD. In Phase 1 studies, once-daily oral 1205 showed good safety, full blockage of GPR84, and favorable drug-like properties. The Proof-of-Concept Phase 2 trial for '1205 was initiated in January 2015 and involves approximately 60 patients with moderate to severe ulcerative colitis.

Galapagos NV Completes 24 Weeks of Treatment of DARWIN 1 and 2 Dose Finding Studies

Galapagos NV announced that the last RA patients in its DARWIN 1 and 2 dose finding studies with filgotinib have completed their final visit. This triggers the clinical research organization's process of last 24 week data collection from both studies, to be followed by final database lock and analysis. Galapagos expects to announce topline results in late July (DARWIN 1) and in August (DARWIN 2) 2015. The last patients in the studies have completed treatment and have now rolled over to DARWIN 3, the open-label, long-term extension study with filgotinib. Results at 12 weeks: The DARWIN 1 and DARWIN 2 studies both met their primary endpoint at 12 weeks of treatment with the selective JAK1 inhibitor filgotinib. Patients in both studies showed improvements in signs and symptoms of active RA and both studies met key efficacy endpoints at 12 weeks of treatment with filgotinib: statistically significant ACR50 scores were achieved with all dose levels and dose regimens, and statistically significant improvement in DAS28(CRP) was seen within one week. Filgotinib was also well tolerated and showed a differentiated safety profile at 12 weeks in RA patients. Hemoglobin levels increased, consistent with JAK1 selectivity. Completion 24 weeks: Filgotinib has now been evaluated in a global Phase 2B program (DARWIN 1, 2 and 3) in 886 RA patients. Topline results from 24 weeks' treatment in DARWIN 1 and 2 will include efficacy scores and unblinded lab and safety information.

Galapagos NV(NasdaqGS:GLPG) added to NASDAQ Composite Index

Galapagos NV has been added to Nasdaq Composite Index.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GLPG:NA €57.69 EUR +0.40

GLPG Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GLPG.
View Industry Companies
 

Industry Analysis

GLPG

Industry Average

Valuation GLPG Industry Range
Price/Earnings NM Not Meaningful
Price/Sales -- Not Meaningful
Price/Book 7.6x
Price/Cash Flow 60.7x
TEV/Sales 20.3x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact GALAPAGOS NV, please visit www.glpg.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.